225 related articles for article (PubMed ID: 17516711)
1. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
2. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
Mouillac B; Mendre C
Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
[TBL] [Abstract][Full Text] [Related]
4. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
5. V2R mutations and nephrogenic diabetes insipidus.
Bichet DG
Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
Mouillac B; Mendre C
Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
8. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2006 Aug; 291(2):F257-70. PubMed ID: 16825342
[TBL] [Abstract][Full Text] [Related]
9. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic diabetes insipidus.
Morello JP; Bichet DG
Annu Rev Physiol; 2001; 63():607-30. PubMed ID: 11181969
[TBL] [Abstract][Full Text] [Related]
11. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
Bichet DG; Bockenhauer D
Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):263-76. PubMed ID: 27156763
[TBL] [Abstract][Full Text] [Related]
12. AVPR2 variants and V2 vasopressin receptor function in nephrogenic diabetes insipidus.
Wildin RS; Cogdell DE; Valadez V
Kidney Int; 1998 Dec; 54(6):1909-22. PubMed ID: 9853256
[TBL] [Abstract][Full Text] [Related]
13. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
14. An X-linked NDI mutation reveals a requirement for cell surface V2R expression.
Sadeghi HM; Innamorati G; Birnbaumer M
Mol Endocrinol; 1997 Jun; 11(6):706-13. PubMed ID: 9171234
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic diabetes insipidus.
Bichet DG
Adv Chronic Kidney Dis; 2006 Apr; 13(2):96-104. PubMed ID: 16580609
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin receptor mutations causing nephrogenic diabetes insipidus.
Bichet DG; Turner M; Morin D
Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088
[TBL] [Abstract][Full Text] [Related]
17. Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus.
Faerch M; Christensen JH; Rittig S; Johansson JO; Gregersen N; de Zegher F; Corydon TJ
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1518-25. PubMed ID: 19812297
[TBL] [Abstract][Full Text] [Related]
18. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
[TBL] [Abstract][Full Text] [Related]
19. Vasopressin receptor mutations in nephrogenic diabetes insipidus.
Bichet DG
Semin Nephrol; 2008 May; 28(3):245-51. PubMed ID: 18519085
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature.
Neocleous V; Skordis N; Shammas C; Efstathiou E; Mastroyiannopoulos NP; Phylactou LA
Metabolism; 2012 Jul; 61(7):922-30. PubMed ID: 22386940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]